Literature DB >> 2083953

Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2.

G Karupiah1, B Coupar, I Ramshaw, D Boyle, R Blanden, M Andrew.   

Abstract

Vaccinia virus was shown to replicate in the ovaries of normal inbred mice and cause sufficient damage to ovarian follicles to decrease fertility of the mice. The mouse-adapted strain, VV-WR, had a greater affinity for growth in ovaries than the vaccine strains, VV-Elstree, VV-NYBH or VV-Copenhagen. Virus reached the ovaries after intravenous or intraperitoneal inoculation, but not after subcutaneous inoculation in the foot pad. Interleukin-2 (IL-2), when expressed by a recombinant vaccinia virus was able to decrease the titre of virus in the ovaries and prevent infertility. Both non-specific (natural killer cells) and antigen-specific mechanisms were active within the ovaries and may play a role in the IL-2-mediated clearance of vaccinia virus.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2083953     DOI： 10.1038/icb.1990.44

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


  15 in total

1.  Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-β.

Authors:  Yuan Zhao; Yan Fei Adams; Michael Croft
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

2.  Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis.

Authors:  Audrey M Chen; Nivedita Khanna; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Effector-like CD8⁺ T cells in the memory population mediate potent protective immunity.

Authors:  Janelle A Olson; Cameron McDonald-Hyman; Stephen C Jameson; Sara E Hamilton
Journal:  Immunity       Date:  2013-06-06       Impact factor: 31.745

4.  Vaccinia virus infection during murine pregnancy: a new pathogenesis model for vaccinia fetalis.

Authors:  Nicola Benning; Daniel E Hassett
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.

Authors:  S Chalikonda; M H Kivlen; M E O'Malley; X D Eric Dong; J A McCart; M C Gorry; X-Y Yin; C K Brown; H J Zeh; Z S Guo; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

6.  Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts.

Authors:  Mirko Trilling; Vu Thuy Khanh Le; Albert Zimmermann; Holger Ludwig; Klaus Pfeffer; Gerd Sutter; Geoffrey L Smith; Hartmut Hengel
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.

Authors:  Mostafa Jarahian; Manuela Fiedler; André Cohnen; Dominik Djandji; Günter J Hämmerling; Cornelius Gati; Adelheid Cerwenka; Peter C Turner; Richard W Moyer; Carsten Watzl; Hartmut Hengel; Frank Momburg
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

8.  Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.

Authors:  G P Bembridge; J A Lopez; R Cook; J A Melero; G Taylor
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.

Authors:  Marina Zaitseva; Elisabeth Shotwell; John Scott; Stephanie Cruz; Lisa R King; Jody Manischewitz; Claudia G Diaz; Robert A Jordan; Douglas W Grosenbach; Hana Golding
Journal:  J Virol       Date:  2013-03-06       Impact factor: 6.549

10.  Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Authors:  Edgar Turner Overton; Jack Stapleton; Ian Frank; Shawn Hassler; Paul A Goepfert; David Barker; Eva Wagner; Alfred von Krempelhuber; Garth Virgin; Thomas Peter Meyer; Jutta Müller; Nicole Bädeker; Robert Grünert; Philip Young; Siegfried Rösch; Jane Maclennan; Nathaly Arndtz-Wiedemann; Paul Chaplin
Journal:  Open Forum Infect Dis       Date:  2015-05-05       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.